CIM
BMRN icon

Contravisory Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Contravisory Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-46,134
Closed -$4.1M – 279
2019
Q1 		$4.1M Sell
46,134
-500
-1% -$46.3K 1.59% 31
2018
Q4 		$3.97M Buy
+46,634
New +$4.44M 1.71% 30

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Contravisory Investment Management's BMRN Position: Q2 2019 in Review

Contravisory Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 46,134 shares — an estimated $4.1M sold.

Contravisory Investment Management first reported a position in BMRN in Q4 2018 and held it in 2 quarters. The position peaked at $4.1M in Q1 2019. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

  • Contravisory Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Contravisory Investment Management sold 46,134 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $4.1M.
  • Contravisory Investment Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Contravisory Investment Management's BioMarin Pharmaceuticals position peaked at $4.1M in Q1 2019.
  • 482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Contravisory Investment Management's 13F filing for Q2 2019, filed 9 Jul 2019.